Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.6% and free cash flow grew 67.0%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow TPST
Tempest Therapeutics, Inc. (TPST) EV/Sales
As of 16 October 2026, Tempest Therapeutics, Inc. (TPST) trades at a EV/Sales of 33.7×. Over the past ten years it has ranged from −202× (January 2019) to 581× (March 2016); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2016 | −91.4× | — |
| FY2015 | 501× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2017 | −78.5× | — |
| Jun 2017 | −66.4× | — |
| Mar 2017 | −56.8× | — |
| Dec 2016 | −91.4× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHIO Phio Pharmaceuticals Corp. compare | −19.5× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −0.1× |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| PTN Palatin Technologies, Inc. compare | 0.7× |
| BLRX BioLineRx Ltd. compare | 1.9× |
| TPST Tempest Therapeutics, Inc. | 33.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)